Monoclonal Antibodies Block GPNMB in Parkinson’s Study, Halting Protein Spread Across 1,675 Brains
Updated
Updated · SciTechDaily · May 20
Monoclonal Antibodies Block GPNMB in Parkinson’s Study, Halting Protein Spread Across 1,675 Brains
2 articles · Updated · SciTechDaily · May 20
Penn researchers reported in Neuron that anti-GPNMB monoclonal antibodies stopped the cell-to-cell spread of alpha-synuclein clumps in cultured-neuron experiments, pointing to a potential way to slow Parkinson’s progression rather than just treat symptoms.
GPNMB appears to sit in a self-reinforcing cycle: damaged neurons trigger microglia to produce more of the immune-related protein, enzymes release it from the cell surface, and the secreted protein then helps alpha-synuclein pathology move into nearby cells.
1,675 brain samples from the Penn Brain Bank backed the lab findings: people with genetic variants tied to higher GPNMB production showed more widespread alpha-synuclein pathology, while higher GPNMB was not linked to markers of disorders such as Alzheimer’s.
The work builds on a 2022 finding that flagged GPNMB as a driver of alpha-synuclein spread, but the team said translation to human treatment remains early despite the need—more than 1 million Americans live with Parkinson’s and about 90,000 new cases are diagnosed yearly.
After past antibody therapies failed, can a new protein target finally halt Parkinson's progression?
A new study targets brain immunity to fight Parkinson's. Is inflammation the real enemy?
GPNMB Antibody Therapy: A Breakthrough Approach to Halting Parkinson’s Disease Progression
Overview
Groundbreaking research led by the University of Pennsylvania has revealed a promising new approach for treating Parkinson's disease. The core discovery is that monoclonal antibodies can target and block the spread of toxic alpha-synuclein protein clumps, which are a hallmark of Parkinson's progression. This breakthrough centers on the critical role of GPNMB, a brain protein that helps spread alpha-synuclein pathology. By focusing on GPNMB, scientists hope to develop a therapy that goes beyond symptom management and actually slows or halts the disease, offering new hope for people with Parkinson's.